Liver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoring

scientific article published on 02 July 2019

Liver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoring is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/S41436-019-0561-7
P698PubMed publication ID31263214

P50authorPriya S KishnaniQ83248117
Carine HalabyQ88868481
P2093author name stringBrian Smith
Sarah P Young
Stephanie Austin
Gary R Schooler
Deeksha Bali
Alisha M Mavis
Surekha Pendyal
Lani K Clinton
Jariya Upadia
Ela Stefanescu
P2860cites workMolecular analysis of the AGL gene: heterogeneity of mutations in patients with glycogen storage disease type III from Germany, Canada, Afghanistan, Iran, and Turkey.Q54575766
Molecular analysis of the AGL gene: Identification of 25 novel mutations and evidence of genetic heterogeneity in patients with Glycogen Storage Disease Type IIIQ56697963
Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatmentQ67720940
Urinary excretion of a glucose-containing tetrasaccharide. A parameter for increased degradation of glycogenQ67928042
Glycogen storage disease type III (glycogen debranching enzyme deficiency): correlation of biochemical defects with myopathy and cardiomyopathyQ68116950
The Subgroups of Type III GlycogenosisQ70923890
Type IIIb glycogen storage disease associated with end-stage cirrhosis and hepatocellular carcinoma. The Liver Transplant GroupQ73107781
Hepatocellular carcinoma complicating liver cirrhosis in type IIIa glycogen storage diseaseQ74067512
Fatal liver cirrhosis and esophageal variceal hemorrhage in a patient with type IIIa glycogen storage diseaseQ77950626
Elevated serum biotinidase activity in hepatic glycogen storage disorders--a convenient biomarkerQ81579416
Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of childrenQ83525974
Hepatocellular Adenomas and Carcinoma in Asymptomatic, Non-Cirrhotic Type III Glycogen Storage DiseaseQ86961871
Role of continuous glucose monitoring in the management of glycogen storage disordersQ88868484
Glycogen storage disease type III diagnosis and management guidelinesQ28287932
Concordance of non-invasive mechanical and serum tests for liver fibrosis evaluation in chronic hepatitis CQ30360178
Liver transplantation for glycogen storage disease types I, III, and IVQ33797826
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyQ34465792
Markedly elevated serum transaminases in glycogen storage disease type IIIQ35206365
Characterization of a canine model of glycogen storage disease type IIIaQ36359220
Cardiac Pathology in Glycogen Storage Disease Type IIIQ36590950
Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?Q36695473
Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome.Q37180852
Mouse model of glycogen storage disease type III.Q39234934
Type III glycogenosis presenting as liver disease in adults with atypical histological featuresQ39508441
Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literatureQ41460619
Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV.Q42982768
Glycogen storage disease type III: A novel Agl knockout mouse model.Q43433907
Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution–electrospray ionization tandem mass spectrometryQ44414194
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT valuesQ44458156
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.Q44527614
A simple, rapid test for the differential diagnosis of glycogen storage disease type 3.Q44555356
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionQ44920531
Role of two-dimensional shear wave elastography in the assessment of chronic liver diseasesQ46487453
Circulating fibroblast growth factor 21 in patients with liver cirrhosisQ48027127
Late presentation of glycogen storage disease types Ia and III in children with short stature and hepatomegalyQ49642749
Chronic hepatitis. An update on terminology and reporting.Q53635198
P433issue12
P921main subjectglycogen storage diseaseQ1421738
P304page(s)2686-2694
P577publication date2019-07-02
P1433published inGenetics in MedicineQ15765508
P1476titleLiver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoring
P478volume21

Reverse relations

cites work (P2860)
Q97423859A Novel Gene Therapy Approach for GSD III Using an AAV Vector Encoding a Bacterial Glycogen Debranching Enzyme
Q92994170Chronic liver disease and impaired hepatic glycogen metabolism in argininosuccinate lyase deficiency
Q89739213Dietary lipids in glycogen storage disease type III: A systematic literature study, case studies, and future recommendations
Q97885773Normalization of obstructive cardiomyopathy and improvement of hepatopathy on ketogenic diet in patient with glycogen storage disease (GSD) type IIIa
Q97517813Response to Heiner-Fokkema et al
Q97517804The multiple faces of urinary glucose tetrasaccharide as biomarker for patients with hepatic glycogen storage diseases
Q94553548Urine glucose tetrasaccharide: A good biomarker for glycogenoses type II and III? A study of the French cohort

Search more.